Overall, these data indicate that DOX treatment affects BCC and CRC cells differently, causing a decrease in MDA-MB-231 cells and an increase of PD-L1 expression in HCT116 CRC cells both in RNA and protein levels. The gene discussed is CD274; the disease is colorectal carcinoma.